Skip to content

A clinical study to asses the Safety, Tolerability and In-use efficacy study of test product

An open label clinical study to evaluate the Safety, Tolerability and In-use efficacy study of HBCR-011805

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043185
Enrollment
45
Registered
2022-06-13
Start date
Unknown
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Himalaya wellness company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult population: 1. Healthy adult subjects of either sex aged between 18 to 45 years. 2. Subjects willing to refrain taking any other similar products during the study period 3. Adult subjects who have not participated in this kind of trial in the past 4 weeks 4. Adult subjects willing to sign informed consent and follow the study procedure. Children and target Population: 1. Healthy male and female subjects aged between 3 months to 12 years depends on the stages. 2. Subjects with nasal congestion, stuffy nose, discomfort in breathing due to nasal congestion. 3. Parents/Guardians/Caregiver related to subjects 4. Subjects aged > 7 years of age willing to provide oral consent for his/her participation in the study along with parents/guardians/caregiver consent (Refer protocol section 11.4, Informed Consent Process) 5. Subjects not using similar products during the study period. 6. Subjects willing to refrain taking any other similar products during the study period 7. Subjects who have not participated in this kind of trial in the past 4 weeks. 8. Parents/ Guardians/ Caregivers of the subjects willing to sign informed consent/assent (as applicable) and follow the study procedure.

Exclusion criteria

Exclusion criteria: 1. Subjects with clinically significant serious cardiovascular, respiratory, cerebrovascular, hepatic, renal disease, endocrinal, congenital or any other disorder. 2. A known history or present condition of allergic response to the study products its components or ingredients in the investigational product. 3. Pre-existing systemic disease necessitating long-term medications. 4. Subjects who refused to sign informed consent. 5. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
1. Occurrence of any adverse or serious adverse events during the study period. Timepoint: Visit 1/ day 1 Visit 2/ day 7

Secondary

MeasureTime frame
Overall compliance of the subject to the study medication Timepoint: Visit 1/ day 1 Visit 2/ day 7

Countries

India

Contacts

Public ContactDr Soorya Narayan H

Himalaya wellness company

dr.swathi.b@himalayawellness.com9538969888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026